-
Signature
-
/s/ Avraham S. Adler, Attorney-in-Fact
-
Issuer symbol
-
PTCT
-
Transactions as of
-
11 Sep 2025
-
Net transactions value
-
-$1,090,400
-
Form type
-
4
-
Filing time
-
15 Sep 2025, 17:00:09 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Boulding Mark Elliott |
EXEC. VP AND CLO |
C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN |
/s/ Avraham S. Adler, Attorney-in-Fact |
15 Sep 2025 |
0001578852 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$679,628 |
+17,838 |
+17% |
$38.10 |
121,739 |
11 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$1,088,118 |
-17,838 |
-15% |
$61.00 |
103,901 |
11 Sep 2025 |
Direct |
F1, F2 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$89,764 |
+2,356 |
+2.3% |
$38.10 |
106,257 |
11 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$143,716 |
-2,356 |
-2.2% |
$61.00 |
103,901 |
11 Sep 2025 |
Direct |
F1, F3 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$94,107 |
+2,470 |
+2.4% |
$38.10 |
106,371 |
11 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$150,670 |
-2,470 |
-2.3% |
$61.00 |
103,901 |
11 Sep 2025 |
Direct |
F1, F4 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$863,384 |
+22,661 |
+22% |
$38.10 |
126,562 |
12 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$1,356,436 |
-22,117 |
-17% |
$61.33 |
104,445 |
12 Sep 2025 |
Direct |
F1, F5 |
| transaction |
PTCT |
Common Stock |
Sale |
$33,777 |
-544 |
-0.52% |
$62.09 |
103,901 |
12 Sep 2025 |
Direct |
F1, F6 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$38,824 |
+1,019 |
+0.98% |
$38.10 |
104,920 |
12 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$62,475 |
-1,019 |
-0.97% |
$61.31 |
103,901 |
12 Sep 2025 |
Direct |
F1, F7 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$34,480 |
+905 |
+0.87% |
$38.10 |
104,806 |
12 Sep 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
$55,395 |
-905 |
-0.86% |
$61.21 |
103,901 |
12 Sep 2025 |
Direct |
F1, F8 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-17,838 |
-33% |
$0.000000 |
36,162 |
11 Sep 2025 |
Common Stock |
17,838 |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-2,356 |
-6.5% |
$0.000000 |
33,806 |
11 Sep 2025 |
Common Stock |
2,356 |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-2,470 |
-7.3% |
$0.000000 |
31,336 |
11 Sep 2025 |
Common Stock |
2,470 |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-22,661 |
-72% |
$0.000000 |
8,675 |
12 Sep 2025 |
Common Stock |
22,661 |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1,019 |
-12% |
$0.000000 |
7,656 |
12 Sep 2025 |
Common Stock |
1,019 |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-905 |
-12% |
$0.000000 |
6,751 |
12 Sep 2025 |
Common Stock |
905 |
$38.10 |
Direct |
F1, F9 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: